Haymarket Medical names Barone as JAAPA publisher

Share this article:
Haymarket Medical has named Dominic Barone publisher of the Journal of the American Academy of Physician Assistants, a title that Haymarket will begin publishing for AAPA in January.
Barone is formerly of Quadrant HealthCom, and he served as publisher of JAAPA for several years while working for Medical Economics. At Haymarket, he reports to Prescribing Reference Inc. chief executive Mark Bugni.
"I'm glad to be back working with the PA market and JAAPA," said Barone. "It is a rapidly growing profession, which delivers quality healthcare and increasing attention from pharmaceutical marketers."
The AAPA awarded the publishing contract for its journal to Haymarket this summer following a competitive pitch. It is currently published by Advanstar/Medical Economics. JAAPA leads its field in readership and ad exposures, with a circulation of 63,000 clinically practicing PAs and PA students, and generated roughly $1 million in revenue last year, according to industry estimates.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...